Deutsche Bank AG reissued their hold rating on shares of AbbVie Inc. (NYSE:ABBV) in a research report released on Monday. They currently have a $66.00 price objective on the stock, up from their prior price objective of $65.00.

Other research analysts also recently issued research reports about the company. Jefferies Group LLC reaffirmed a buy rating and issued a $94.00 price objective (up previously from $92.00) on shares of AbbVie in a research note on Monday. Zacks Investment Research raised AbbVie from a sell rating to a hold rating in a research note on Thursday, July 13th. Vetr raised AbbVie from a hold rating to a buy rating and set a $74.86 price objective on the stock in a research note on Thursday, July 6th. Leerink Swann set a $71.00 price objective on AbbVie and gave the stock a hold rating in a research note on Thursday, April 20th. Finally, BMO Capital Markets reaffirmed a hold rating and issued a $63.00 price objective on shares of AbbVie in a research note on Wednesday, March 22nd. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. AbbVie presently has a consensus rating of Buy and a consensus target price of $74.52.

Shares of AbbVie (NYSE:ABBV) opened at 74.01 on Monday. The company has a 50-day moving average price of $71.21 and a 200-day moving average price of $65.76. The company has a market capitalization of $117.79 billion, a PE ratio of 19.18 and a beta of 1.51. AbbVie has a 52 week low of $55.06 and a 52 week high of $74.22.

AbbVie (NYSE:ABBV) last posted its earnings results on Thursday, April 27th. The company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.02. AbbVie had a return on equity of 148.83% and a net margin of 24.07%. The company had revenue of $6.54 billion for the quarter, compared to the consensus estimate of $6.49 billion. During the same quarter in the prior year, the company earned $1.15 earnings per share. AbbVie’s revenue was up 9.7% on a year-over-year basis. Analysts predict that AbbVie will post $5.53 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally published by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.watchlistnews.com/abbvies-nyseabbv-hold-rating-reiterated-at-deutsche-bank-ag/1454097.html.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Friday, July 14th will be paid a dividend of $0.64 per share. This represents a $2.56 dividend on an annualized basis and a dividend yield of 3.46%. The ex-dividend date is Wednesday, July 12th. AbbVie’s dividend payout ratio is currently 66.32%.

In other AbbVie news, EVP Carlos Alban sold 43,000 shares of AbbVie stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $67.00, for a total transaction of $2,881,000.00. Following the completion of the sale, the executive vice president now directly owns 114,745 shares of the company’s stock, valued at approximately $7,687,915. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Laura J. Schumacher sold 79,800 shares of AbbVie stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $70.00, for a total value of $5,586,000.00. Following the sale, the insider now directly owns 187,625 shares of the company’s stock, valued at $13,133,750. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 278,135 shares of company stock valued at $18,841,085. 0.23% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of ABBV. Norges Bank purchased a new stake in shares of AbbVie during the fourth quarter worth $823,984,000. Glenview Capital Management LLC bought a new position in AbbVie during the fourth quarter valued at approximately $570,905,000. Asset Management One Co. Ltd. raised its position in AbbVie by 471.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 2,801,318 shares of the company’s stock valued at $175,449,000 after buying an additional 2,311,080 shares during the last quarter. State Street Corp raised its position in AbbVie by 2.4% in the first quarter. State Street Corp now owns 72,969,530 shares of the company’s stock valued at $4,754,696,000 after buying an additional 1,696,042 shares during the last quarter. Finally, Wedge Capital Management L L P NC bought a new position in AbbVie during the first quarter valued at approximately $46,744,000. 68.04% of the stock is owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.